The role of aberrant NIK activity in driving DLBCL lymphomagenesis has been verified in a mouse model with constitutive transgenic NIK and BCL6 expression in GC and post-GC B cells [67]. This evidence concerns the gene MAP3K14 and diffuse large B-cell lymphoma.